Meloxicam Oral Suspension Label Tightens Safety Focus on Dogs and Cats
The updated label for meloxicam oral suspension keeps the therapeutic message straightforward: this is a veterinary NSAID for oral use in dogs only, and the margin for error is narrow. The product is labeled at 1.5 mg/mL and carries a boxed warning that repeated use in cats has been associated with acute renal failure and death. That warning is not a peripheral line item. It defines the boundaries of use and makes species selection part of the drug’s core safety profile.
Meloxicam belongs to the oxicam class of non-steroidal anti-inflammatory drugs. In dogs, the suspension is indicated for the control of pain and inflammation associated with osteoarthritis. The formulation is designed for practical dosing, but the clinical intent remains the same as with any NSAID: suppress inflammatory pain while limiting exposure to the lowest effective dose for the shortest duration consistent with individual response.
Species Restriction and the Boxed Warning Drive the Risk Message
The most consequential safety statement on the label is directed at feline use. Repeated meloxicam exposure in cats has been linked to acute renal failure and death, and the label explicitly says not to administer additional injectable or oral meloxicam to cats. The contraindication is equally direct: cats should not receive this product. In everyday veterinary practice, that means the drug should be handled as a dog-specific treatment, not as a transferable option across species with similar musculoskeletal complaints.
A one-sentence warning does not capture the clinical gravity. Cats with reduced renal reserve may deteriorate quickly when prostaglandin-dependent renal perfusion is disrupted, and repeated exposure compounds that vulnerability. For veterinarians, the label’s message is less about caution in the abstract and more about avoiding a predictable renal catastrophe.
Dogs face a different but still meaningful safety profile. Meloxicam is contraindicated in dogs with known hypersensitivity to the drug. The label also advises against use in dogs younger than 6 months, in breeding dogs, and in pregnant or lactating dogs because safe use in those groups has not been evaluated. Dogs with bleeding disorders are another group in whom use is not recommended, reflecting the broader NSAID concern for gastrointestinal and hemostatic complications.
Dosing Precision Matters More in Small Dogs
The dosing instructions reflect how easily an apparently routine NSAID can become unsafe if delivery is imprecise. The labeled initial dose is 0.09 mg/lb, or 0.2 mg/kg, on the first day only. After that, the maintenance dose is 0.045 mg/lb, or 0.1 mg/kg, once daily. The suspension is packaged with two dosing syringes: a small syringe for dogs under 5 pounds and a large syringe for dogs 5 pounds and above.
Small dogs receive the strictest administration rules. The label says the small syringe should be used for dogs under 5 pounds, with dosing marks beginning at 1 pound and increasing in 1-pound increments. The dog’s weight should be rounded down to the nearest pound increment. The suspension should be placed on food only, not given directly into the mouth, and the bottle should never be used as a dropper. Those instructions are not cosmetic. They are built to reduce overdosing in animals where even small measurement errors can matter disproportionately.
Dogs over 5 pounds may receive the suspension mixed with food or placed directly into the mouth, but dosing remains tied to the calibrated syringe and to rounded-down weight increments in 5-pound steps. The package instructions make clear that accuracy, not convenience, is the central concern.
Gastrointestinal Effects Lead the Field Safety Profile
Field safety was evaluated in 306 dogs across two studies, with 157 receiving meloxicam and 149 receiving placebo. Gastrointestinal abnormalities were the most common adverse reactions. Vomiting occurred in 40 dogs in the meloxicam group versus 23 in the placebo group. Diarrhea or soft stool occurred in 19 versus 11 dogs. The label also lists bloody stool, inappetance, bleeding gums after a dental procedure, lethargy or swollen carpus, and epiphora among observed clinical events.
Those findings fit the class effect expected of cyclo-oxygenase inhibitory NSAIDs. Gastric irritation, altered mucosal defense, and GI bleeding are among the best-known complications of this drug class, especially when dosing errors, dehydration, or concurrent therapies compound the risk. In practical terms, a dog that stops eating, vomits repeatedly, develops melena, or becomes lethargic while receiving meloxicam deserves prompt reassessment rather than continued dosing by habit.
The post-approval experience adds a broader cautionary layer. Reported adverse events include vomiting, anorexia, diarrhea, melena, gastrointestinal ulceration, azotemia, elevated creatinine, renal failure, lethargy, depression, elevated liver enzymes, and pruritus. Death has been reported as an outcome of these events. The label does not assign frequency or causality to these reports, but it does define the range of toxicity that clinicians should keep in view when an animal worsens after exposure.
Baseline Screening and Drug Interactions Are Part of Routine Use
Before starting therapy, the label calls for a thorough history and physical examination and recommends baseline hematologic and serum biochemical testing, with periodic monitoring during treatment. That guidance is especially relevant in dogs with dehydration or pre-existing renal, cardiovascular, or hepatic dysfunction, because those animals are at greatest risk for renal toxicity. NSAIDs can suppress prostaglandins that help maintain normal homeostatic function, and the resulting loss of physiologic reserve may unmask disease that was not previously recognized.
Concomitant use with other anti-inflammatory drugs, including other NSAIDs and corticosteroids, should be avoided because of the risk of gastrointestinal ulceration and perforation. If more analgesia is needed after the total daily dose has been given, the label advises a non-NSAID and non-corticosteroid option instead. Washout periods matter when switching from corticosteroids to meloxicam or from one NSAID to another. The label also notes that the effects of concomitant protein-bound drugs and agents that may inhibit meloxicam metabolism have not been evaluated in dogs, so adjunctive therapy should be handled with care.
Practical Takeaway for Veterinary Prescribers
The updated labeling puts the emphasis where it belongs: species-specific prescribing, exact dosing, and close monitoring for renal and gastrointestinal toxicity. Meloxicam can be a useful analgesic for canine osteoarthritis, but the label leaves little room for casual use. It should be kept away from cats entirely, used cautiously in dogs with compromised organ function, and dispensed only with clear client instructions and the correct syringe.
The unresolved question in daily practice is not whether the drug works for inflammatory pain in dogs. The question is how reliably clinicians can prevent dosing mistakes, dehydration-related toxicity, and unsafe overlap with other anti-inflammatory agents in the patients most likely to need chronic pain control.